Herceptin Current Events | Herceptin News
|
|
|
Sort By:
Page Views | Date |
Breast cancer drug receives FDA approval
A new use for the breast cancer drug Herceptin was approved by the FDA yesterday, a move that means more treatment options for the 25 percent of breast cancer patients with early-stage HER-2 positive breast cancer. view more (2006-11-20)
Study finds cardiac toxicity rates high with herceptin use
The first study to look at "real world" use of Herceptin in advanced breast cancer patients found a higher incidence of cardiac toxicity - 28 percent of patients treated - than clinical trials of the drug have reported to date, but also concluded that the majority of this heart damage could be reversed with treatment. view more (2006-08-15)
Gene profiling predicts resistance to breast cancer drug Herceptin
Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer. view more (2007-02-21)
New Herceptin results confirm impressive reduction in risk of cancer returning
New Herceptin results confirm impressive reduction in risk of cancer returning in women with aggressive form of early-stage breast cancer. view more (2005-09-14)
Canadian cardiology team clears the way for lifesaving breast cancer treatment
A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society. view more (2009-10-26)
Herceptin does not increase heart failure in patients long-term
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31. view more (2007-06-04)
Herceptin plus chemotherapy significantly increases disease-free survival in breast cancer
Combining the molecularly targeted therapy Herceptin with chemotherapy in women with early stage breast cancer significantly improves disease-free survival for patients with a specific genetic mutation that results in very aggressive disease. view more (2006-12-18)
M. D. Anderson study finds change in HER2 status after treatment with Herceptin
Researchers at The University of Texas M. D. Anderson Cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. view more (2008-09-04)
Herceptin treatment lowers recurrence rate in early breast cancer
The targeted drug trastuzumab, or Herceptin, previously shown to prolong survival in advanced breast cancer, dramatically reduced the chances of recurrence in patients with early-stage disease when given for one year following standard chemotherapy. view more (2005-10-20)
Nanoscopic probes can track down and attack cancer cells
A researcher has developed probes that can help pinpoint the location of tumors and might one day be able to directly attack cancer cells. view more (2009-03-16)
Researchers call for wider implementation of FISH testing in metastatic breast cancer
Accurate diagnostic assessment of HER2 is essential for the effective treatment of metastatic breast cancer. Results to be published in the April issue of the Journal of Pathology indicate that FISH testing has many advantages over other methods, however in the UK there are very few diagnostic laboratories with the expertise to carry out the test.... view more... (2003-02-26)
Reining in cancer - first laboratory study to show that combining novel targeted therapiesmay keep cancer cells under control
A team of Italian researchers has demonstrated in the laboratory for the first time that combining two of the newest anti-cancer targeted agents may produce a powerful new combination against breast cancer - and possibly many other cancers as well. Their findings are reported (Thursday 24 January) in the journal Annals of Oncology.* They found... view more... (2002-01-21)
Early-stage, HER2-positive breast cancer patients at increased risk of recurrence
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. view more (2009-11-03)
Can healthcare systems afford Herceptin for early breast cancer?
New research into the cost of using the breast cancer drug Herceptin warns that healthcare authorities and the organisations advising them should not rush to prescribe it for early breast cancer without working out extremely carefully the budget implications and cost-effectiveness of the drug. view more (2005-11-30)
Herceptin gives disappointing results in lung cancer trial
Trastuzumab (Herceptin) - a treatment that has increased survival in many breast cancer patients - has failed to live up to hopes that it might also help lung cancer patients. view more (2004-01-08)
Triple drug combination is promising option to treat metastatic HER2+ breast cancer
Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options. view more (2009-05-15)
First European trial for new breast cancer vaccine
European clinical trials are under way in Denmark and the UK testing a new breast cancer vaccine targeted against the HER-2 growth factor.* HER-2 is overexpressed in about a quarter of all breast cancers and has become a key target for new treatments, such as the monoclonal antibody therapy Herceptin. But, the development of a vaccine by Danish... view more... (2002-03-18)
Headlines about Herceptin show equality of access to costly drugs must be tackled
The recent press coverage on the use of Herceptin (brand name for the drug trastuzumab) for treating breast cancer in its early stages shows that issues of equal access to costly but effective drugs must be confronted, says an editorial in this week's BMJ. view more (2005-11-04)
Primrose oil component cuts levels of cancer-causing gene Her-2/neu
Gamma-linolenic acid (GLA), a substance in evening primrose oil and several other plant oils used in herbal medicine, inhibits action of Her-2/neu, a cancer gene that is responsible for almost 30 percent of all breast cancers. view more (2005-11-02)
FDA approved leukemia drugs shows promise in ovarian cancer cells
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. view more (2009-11-10)
|
|
|
|
Sort By:
Page Views | Date |
|
